

# Ananya Choudhury

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4100989/publications.pdf>

Version: 2024-02-01

109  
papers

3,736  
citations

147801

31  
h-index

138484

58  
g-index

111  
all docs

111  
docs citations

111  
times ranked

5217  
citing authors

#	ARTICLE	IF	CITATIONS
1	MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer. <i>Cancer Research</i> , 2010, 70, 7017-7026.	0.9	184
2	A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , 2010, 42, 415-419.	21.4	169
3	Phase II Study of Conformal Hypofractionated Radiotherapy With Concurrent Gemcitabine in Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 733-738.	1.6	155
4	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 659-665.	1.2	149
5	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , 2015, 16, 417-425.	10.7	137
6	European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. <i>Human Molecular Genetics</i> , 2011, 20, 4268-4281.	2.9	134
7	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 182-189.	6.1	132
8	Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A “Game Changer” for Prostate Treatment?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 361-373.	0.8	132
9	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
10	What Is the Significance of Variant Histology in Urothelial Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 653-663.	3.1	126
11	Similar Treatment Outcomes for Radical Cystectomy and Radical Radiotherapy in Invasive Bladder Cancer Treated at a United Kingdom Specialist Treatment Center. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 456-463.	0.8	121
12	Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 6857-6864.	0.9	107
13	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4761-4768.	7.0	107
14	Magnetic resonance-guided radiation therapy: A review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 163-177.	1.8	104
15	The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. <i>Frontiers in Oncology</i> , 2016, 6, 215.	2.8	100
16	Radiation and New Molecular Agents Part I: Targeting ATM-ATR Checkpoints, DNA Repair, and the Proteasome. <i>Seminars in Radiation Oncology</i> , 2006, 16, 51-58.	2.2	97
17	Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 203-213.	4.1	95
18	Magnetic Resonance Imaging-Guided Radiation Therapy: A Short Strengths, Weaknesses, Opportunities, and Threats Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1057-1060.	0.8	83

#	ARTICLE	IF	CITATIONS
19	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology</i> , The, 2021, 22, 246-255.	10.7	73
20	Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy. <i>Radiation Oncology</i> , 2011, 6, 54.	2.7	67
21	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 40-47.	0.6	54
22	REQUIRE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 138, 59-67.	0.6	53
23	Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy. <i>Clinical Oncology</i> , 2015, 27, 561-569.	1.4	52
24	Radiation Fractionation Schedules Published During the COVID-19 Pandemic: A Systematic Review of the Quality of Evidence and Recommendations for Future Development. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 379-389.	0.8	47
25	Genome-wide association study yields variants at 20p12.2 that associate with urinary bladder cancer. <i>Human Molecular Genetics</i> , 2014, 23, 5545-5557.	2.9	46
26	Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 78-86.	0.8	46
27	Management of bladder cancer in older patients: Position paper of a SIOG Task Force. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1043-1053.	1.0	46
28	Post-treatment lymphocytopenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 115-119.	0.6	42
29	Analysis of variants in DNA damage signalling genes in bladder cancer. <i>BMC Medical Genetics</i> , 2008, 9, 69.	2.1	38
30	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 867-875.	0.8	37
31	Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase III trials. <i>Radiotherapy and Oncology</i> , 2016, 121, 193-198.	0.6	36
32	Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. <i>Oncotarget</i> , 2018, 9, 3946-3955.	1.8	35
33	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. <i>JAMA Oncology</i> , 2017, 3, 68.	7.1	33
34	The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1179-1189.	0.8	33
35	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1407-1415.	0.8	33
36	Organ preservation in bladder cancer: an opportunity for truly personalized treatment. <i>Nature Reviews Urology</i> , 2019, 16, 511-522.	3.8	31

#	ARTICLE	IF	CITATIONS
37	Therapeutic Radiographers at the Helm: Moving Towards Radiographer-Led MR-Guided Radiotherapy. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2020, 51, 364-372.	0.3	28
38	The anti-PD-1 era "an opportunity to enhance radiotherapy for patients with bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 251-259.	3.8	27
39	Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 288-296.	0.8	27
40	Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 732-739.	0.8	26
41	External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 525-533.	0.8	26
42	Bladder Preservation for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 151-163.	0.4	25
43	Technical Note: Investigating the impact of field size on patient selection for the 1.5T $\gamma$ Linac. <i>Medical Physics</i> , 2017, 44, 5667-5671.	3.0	23
44	Palliative Radiation Therapy in Bladder Cancer "Importance of Patient Selection: A Retrospective Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 389-393.	0.8	23
45	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 809-818.	0.8	23
46	The Rationale for Post-Operative Radiation in Localized Bladder Cancer. <i>Bladder Cancer</i> , 2017, 3, 19-30.	0.4	22
47	The Potential Value of MRI in External-Beam Radiotherapy for Cervical Cancer. <i>Clinical Oncology</i> , 2018, 30, 737-750.	1.4	22
48	Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 27-37.	0.8	22
49	Lost in application: Measuring hypoxia for radiotherapy optimisation. <i>European Journal of Cancer</i> , 2021, 148, 260-276.	2.8	21
50	A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. <i>Radiotherapy and Oncology</i> , 2016, 121, 299-303.	0.6	20
51	The hypoxia marker CAIX is prognostic in the UK phase III VortX-Biobank cohort: an important resource for translational research in soft tissue sarcoma. <i>British Journal of Cancer</i> , 2018, 118, 698-704.	6.4	20
52	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020, 5, 26-32.	1.2	19
53	Clinical Oncology in Sri Lanka: Embracing the Promise of the Future. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 466-470.	0.8	16
54	A Deep Learning Approach Validates Genetic Risk Factors for Late Toxicity After Prostate Cancer Radiotherapy in a REQUITE Multi-National Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 541281.	2.8	15

#	ARTICLE	IF	CITATIONS
55	Assessing localized dosimetric effects due to unplanned gas cavities during pelvic MR-guided radiotherapy using Monte Carlo simulations. <i>Medical Physics</i> , 2019, 46, 5807-5815.	3.0	13
56	Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , 2021, 159, 241-248.	0.6	11
57	Radiotherapy for High-grade T1 Bladder Cancer. <i>European Urology Focus</i> , 2018, 4, 506-508.	3.1	10
58	Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 499-506.	0.6	10
59	Selection of endogenous control genes for normalising gene expression data derived from formalin-fixed paraffin-embedded tumour tissue. <i>Scientific Reports</i> , 2020, 10, 17258.	3.3	10
60	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review. <i>Clinical Oncology</i> , 2020, 32, 347-353.	1.4	10
61	Developing Tumor Radiosensitivity Signatures Using LncRNAs. <i>Radiation Research</i> , 2021, 195, 324-333.	1.5	10
62	Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 75-82.	0.6	10
63	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575909.	2.8	10
64	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). <i>British Journal of Cancer</i> , 2017, 116, 649-657.	6.4	9
65	Comparing Clinical Outcomes for Radium-223: Do Older Patients Do Worse?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 955-957.	0.8	8
66	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 33-35.	0.8	8
67	The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 1767-1772.	2.2	8
68	A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20190760.	2.2	8
69	The role of palliative radiotherapy in bladder cancer: a narrative review. <i>Annals of Palliative Medicine</i> , 2020, 9, 4294-4299.	1.2	8
70	Parametrized rectal dose and associations with late toxicity in prostate cancer radiotherapy. <i>British Journal of Radiology</i> , 2015, 88, 20150110.	2.2	7
71	Evaluation of the palliative radiotherapy pathway in a single institute: Can an MR Linac improve efficiency?. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2022, 53, S44-S50.	0.3	7
72	Adjuvant Chemotherapy Is More Suitable Than Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer Patients Treated With Radical Chemoradiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 614-616.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Using the Malthus programme to predict the recruitment of patients to MR-linac research trials in prostate and lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 159-162.	0.6	6
74	Comparison of intensity modulated radiotherapy plan optimisation methods for a 1.5 T MR-Linac. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 43-49.	1.9	6
75	A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. <i>British Journal of Cancer</i> , 2021, 125, 85-93.	6.4	6
76	Development and validation of a hypoxia-associated signature for lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 1290.	3.3	6
77	To see or not to see: Evaluation of magnetic resonance imaging sequences for use in MR Linac-based radiotherapy treatment. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2022, 53, 362-373.	0.3	6
78	BLADDER PRESERVATION MULTIMODALITY THERAPY AS AN ALTERNATIVE TO RADICAL CYSTECTOMY FOR TREATMENT OF MUSCLE INVASIVE BLADDER CANCER. <i>BJU International</i> , 2011, 108, E313.	2.5	5
79	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 957-963.	0.8	5
80	Bladder cancer and the National Cancer Data Base: New insight or misinformation?. <i>Cancer</i> , 2018, 124, 1105-1107.	4.1	5
81	Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer. <i>BMC Urology</i> , 2021, 21, 96.	1.4	5
82	Biomarkers in muscle invasive bladder cancer. <i>Advances in Clinical Chemistry</i> , 2022, 107, 265-297.	3.7	5
83	Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study). <i>Lung Cancer</i> , 2022, 166, 228-241.	2.0	5
84	Radiotherapy respiratory motion management in hepatobiliary and pancreatic malignancies: a systematic review of patient factors influencing effectiveness of motion reduction with abdominal compression. <i>Acta Oncologica</i> , 2022, 61, 833-841.	1.8	5
85	FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 882-893.	1.8	4
86	Photons, Protons, SBRT, Brachytherapy—What Is Leading the Charge for the Management of Prostate Cancer? A Perspective From the GU Editorial Team. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1114-1121.	0.8	4
87	Protecting Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 515-517.	0.8	3
88	Relapsing Prostate Cancer: Castrate or Cure?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1095-1096.	0.8	3
89	Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. <i>European Urology</i> , 2019, 76, 69-70.	1.9	3
90	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 262-275.	3.8	3

#	ARTICLE	IF	CITATIONS
91	The Horse is at the Stable Door: Management of N1M0 Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 199-208.	1.4	3
92	Delivering adaptive radiotherapy to the bladder during radical treatment. <i>Journal of Radiotherapy in Practice</i> , 2013, 12, 195-202.	0.5	2
93	Molecular Biomarkers in Muscle-Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 705-706.	0.8	2
94	The treatment of periarticular soft tissue sarcoma following neo-adjuvant radiotherapy: a cohort study. <i>World Journal of Surgical Oncology</i> , 2015, 13, 108.	1.9	2
95	“But We Are Already Geriatric Oncologists” Why Older Patients Need a Special Approach (A View) <i>TJ ETQq1 1 0.784314 rgBT</i> 2017, 98, 964-965.	0.8	2
96	Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. <i>British Journal of Radiology</i> , 2020, 93, 20190250.	2.2	2
97	Dosimetric Predictors of Radiotherapy-Induced Lymphocytopenia in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, e11-e12.	1.1	1
98	Can Hypofractionation and Immune Modulation Coexist?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 742-744.	0.8	1
99	Single-fraction high-dose-rate (HDR) brachytherapy boost and hypofractionated radiation for intermediate- and high-risk prostate cancer: A report of toxicity from a single center experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 112-112.	1.6	1
100	External Validation of a Predictive Model for Acute Skin Radiation Toxicity in the REQUITE Breast Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 575909.	2.8	1
101	In Reply to Dr. Rosario et al.. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1602.	0.8	0
102	Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy. <i>Journal of Radiotherapy in Practice</i> , 2013, 12, 326-333.	0.5	0
103	Fit Patient with Nonmetastatic Castration-resistant Prostate Cancer, Lower Urinary Tract Symptoms, and Severe Recurrent Haematuria. <i>European Urology Focus</i> , 2016, 2, 477-478.	3.1	0
104	Exploring trends in advanced bladder cancer using the NCDB: turning data into information and information into insight. <i>Translational Andrology and Urology</i> , 2018, 7, 754-756.	1.4	0
105	The Future of Radiotherapy in Bladder Cancer. , 2018, , 123-129.		0
106	SABR versus conventional fractionation regimens in NSCLC. <i>Lancet Oncology</i> , The, 2019, 20, e231.	10.7	0
107	Flattening the Curve of Prostate Cancer Progression: Accurate Detection and Safe Ablation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 609-612.	0.8	0
108	Trimodal Therapy. , 2021, , 257-280.		0

#	ARTICLE	IF	CITATIONS
109	The impact of an educational tool in cervix image registration across three imaging modalities. British Journal of Radiology, 2022, 95, .	2.2	0